News Column

Investigators at Shaanxi Normal University Report Findings in Clinical Trials and Studies (Sonodynamic antitumor effect of a novel sonosensitizer on...

July 21, 2014



Investigators at Shaanxi Normal University Report Findings in Clinical Trials and Studies (Sonodynamic antitumor effect of a novel sonosensitizer on S180 solid tumor)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Clinical Research have been published. According to news reporting out of Shaanxi, People's Republic of China, by NewsRx editors, research stated, "The purpose of this study was to evaluate the sonodynamically induced antitumor effect of a novel sonosensitizer (DVDMS) in mice bearing sarcoma 180 solid tumors. In order to determine the optimum timing of ultrasound exposure after administration of DVDMS, a three-dimensional optical imaging system (IVIS spectrum) was used to observe the biodistribution of DVDMS in S180 tumor."

Our news journalists obtained a quote from the research from Shaanxi Normal University, "The antitumor effects were estimated by the tumor inhibition ratio (volume and weight) after sonodynamic therapy. The experiments suggested that DVDMS has a preferential localization in tumors, but a low accumulation in most normal tissues. A significant synergistic effect of ultrasound combined with DVDMS was obtained when the load power indicated 4 W and DVDMS dose was above 2 mg/kg. At day 14 after DVDMS-SDT, the tumor volume inhibition ratio was 56.27%. In addition, the tumor weight inhibition ratio after the synergistic treatment was 55.37%, which was obviously stronger than ultrasound treatment alone (23.85%) and DVDMS alone (23.15%). Moreover, no metastasis occurred to the tumors in the SDT-treated mice compared with the control group. DVDMS is a potential sensitizer for sonodynamic cancer therapy."

According to the news editors, the research concluded: "The antitumor effect of ultrasound could be enhanced in the presence of DVDMS, which might be involved in a sonochemical mechanism."

For more information on this research see: Sonodynamic antitumor effect of a novel sonosensitizer on S180 solid tumor. Biopharmaceutics & Drug Disposition, 2014;35(1):50-59. Biopharmaceutics & Drug Disposition can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Biopharmaceutics & Drug Disposition - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-081X)

Our news journalists report that additional information may be obtained by contacting C.F. Li, Shaanxi Normal Univ, Coll Life Sci, Key Lab Med Resources & Nat Pharmaceut Chem, Minist EducNatl Engn Lab Resource Dev Endangered, Xian 710062, Shaanxi, People's Republic of China. Additional authors for this research include K. Zhang, P. Wang, J.M. Hu, Q.J. Liu and X.B. Wang (see also Clinical Research).

Keywords for this news article include: Asia, Shaanxi, Clinical Research, People's Republic of China, Clinical Trials and Studies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters